探索不同配置的肝脏微生理系统的潜力,以模拟胆固醇化学效应
Katharina S Nitsche1,2, Courtney Sakolish1, Paul L Carmichael2,3
1Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843, USA.
Archives of toxicology
|December 8, 2025
概括
这项研究比较了肝脏模型的药物安全性,发现PhysioMimix LC12微生理系统 (MPS) 在原发性人肝细胞 (PHH) 和HepaRG细胞中有效检测胆固醇酶生物标志物.
科学领域:
- 肝病学和毒理学 肝病学和毒理学
- 在 Vitro 模型中
- 药物安全评估 药物安全评估
背景情况:
- 人体体外肝脏模型正在进行长期功能和模拟药物诱导胆固醇病变.
- 微生理系统 (MPS) 为肝脏生理学和化学诱导胆固醇病的预测提供了有希望的方法.
研究的目的:
- 在二维培养和三个肝脏MPS中全面比较基底功能和毒剂诱导的影响.
- 为了在不同的模型和时间点中评估HepaRG细胞,原发性人肝细胞 (PHH) 和诱导多能干细胞 (iPSC) 衍生的肝细胞.
主要方法:
- 肝细胞模型 (HepaRG,PHH,iHeps) 在2D和3个MPS (OrganoPlate,PhysioMimix LC12) 中进行培养.
- 基础功能 (白蛋白,尿素,CYP3A4活性,胆酸) 和对胆固醇抑制剂的反应在7-30天内被测量.
- 进行比较的模型包括HepaRG,PHH和iPSC衍生的肝细胞.
主要成果:
- 在2D和PhysioMimix LC12中,HepaRG和PHH显示出可比的肝细胞功能,HepaRG维持功能长达30天.
- 在HepaRG和PHH中,PhysioMimix LC12在暴露于胆固醇抑制剂时检测到胆酸释放的减少.
- 与HepaRG相比,PhysioMimix LC12中的PHH显示了更一致的胆固醇酶生物标志物反应.
结论:
- 肝细胞功能标记在2D和PhysioMimix LC12中的PHH和HepaRG之间是可比的.
- 该PhysioMimix LC12 MPS能够检测胆质酶诱导的胆酸释放的变化.
- 在PhysioMimix LC12中,初级人类肝细胞为胆固醇定位评估提供了更一致的反应.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
250
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
250
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
203
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
203


